Marco Brughera

Part of Baxter International, Inc., Servier IP UK Ltd. is a company that wholesales pharmaceutical products. Servier IP UK Ltd. is based in Slough, UK. Servier IP was acquired by Baxter International, Inc. from Essetifin SpA on July 23, 2015 for $1,255.92 million.

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Accelera SRL operates as an drug discovery development research organization. It offers discovery, development, and bioanalysis and PK services. The company is headquartered in Nerviano, Italy.

Part of Valline Srl, Leadiant Biosciences SpA develops and manufactures pharmaceutical therapies for patients with rare diseases. The company is based in Rome, Italy. The Italian company was founded in 1957. Marco Maria Brughera has been the CEO of the company since 2011. Leadiant Biosciences was acquired by CHIESI Farmaceutici SpA on October 20, 2020.

Sigma-Tau Industrie Farmaceutiche Riunite SpA engages in the provision of biopharmacological research and technology development services. It offers pharmaceutical products for therapeutic areas, such as cardiology and metabolism, gastroenterology, infectious diseases, urology, rheumatology, osteoporosis, neurology, psychiatry, and oncology. The company was founded by Emilio Cavazza and Claudio Cavazza in 1957 and is headquartered in Rome, Italy.

Leadiant Biosciences Ltd. researches, manufactures, and markets therapies for patients. The private company is based in London, UK, and has subsidiaries in Germany. The British company was founded in 1957. Antonio Gama da Silva has been the CEO of the company since 2016.

Naicons Srl develops a game-changing drug discovery platform. The private company is based in Milan, Italy.

Part of Merck KGaA, Exelead, Inc. is a biopharmaceutical contract development and manufacturing company. The company is based in Indianapolis, IN. John Rigg has been the CEO of the company since 2014. Exelead was acquired by Merck KGaA from Leadiant Biosciences SA on February 23, 2022 for $780 million.